Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

K. Jhaveri; H. Han; E. Dotan; D-Y. Oh; C. Ferrario; A. Tolcher; K-W. Lee; C-Y. Liao; Y-K. Kang; Y.H. Kim; E. Hamilton; A. Spira; N. Patel; C. Karapetis; S.Y. Rha; L. Boyken; J. Woolery; P. Bedard

doi:10.1016/j.annonc.2022.07.589

YUHSpace

BROWSE

0 244

Cited 0 times in

Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

Authors: K. Jhaveri ; H. Han ; E. Dotan ; D-Y. Oh ; C. Ferrario ; A. Tolcher ; K-W. Lee ; C-Y. Liao ; Y-K. Kang ; Y.H. Kim ; E. Hamilton ; A. Spira ; N. Patel ; C. Karapetis ; S.Y. Rha ; L. Boyken ; J. Woolery ; P. Bedard